News | June 02, 2026
Ebola vax on the anvil?
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
